



PCAC Meeting Summary

November 29, 2022

Attendees: Abera, Abby, Andrew, Beth, Devan, Emily, Genevieve, Jonah, Julie, Kathleen, Laurie, Marilyn, Marney, Mary, Nadine, Nicole, Patricia, Sabina, Sarah B, Sarah G, Suzanne, Tamara, and Zal.

Opening Remarks

This meeting began with a reflection on the CADTH Board of Directors retreat that took place in September 2022. Our Committee Chair, Marney, shared her reflections on the experience, including her presentation to the board members about this committee. Highlights of the retreat included CADTH's work on real-world evidence; reconciliation with Indigenous Peoples', communities, organizations, and governments; and support needed for CADTH's expert committee members and toward efforts in their recruitment.

CEO Remarks

CADTH's President and CEO, Suzanne McGurn, joined the meeting to share her reflections from the board retreat and give an update on putting the 2022-2025 Strategic Plan into action.

Update on Your Advice to CADTH

Committee members were updated on engagement activities across CADTH and how they fit into the IAP2 [Spectrum of Public Participation](#). There are increased opportunities and new approaches to address accessibility, diversity of perspective, and power imbalances in these projects. CADTH recently published a list of [17 approaches to finding patient partners](#), which was shared with members at this meeting. One member asked if this information could be shared publicly, following which it has been. Finally, members were updated on plans to create a community of patient partners for CADTH projects, and current projects involving patient partners.

Post-Market Drug Evaluation (PMDE)

Members of CADTH's Post-Market Drug Evaluation team came to this meeting to provide an overview of the program since its launch in September. They spoke of the team's role within CADTH and the health system at large, its network of partners, and upcoming engagement opportunities. They also shared examples of the types of questions and requests from partners that the team intends to tackle. Several committee members posed questions about these requests and how PMDE differs from CADTH's drug reimbursement review process.

Real-World Evidence (RWE)

This meeting closed with a presentation from CADTH's Real-World Evidence team, following up on previous visits to this committee. This presentation focused on real-world evidence as part of the health care decision-making process, as well as rare disease registries in Canada. Recent examples of patient and community engagement in the team's work – including valuable lessons learned – were also shared. Committee members were invited to an [upcoming consultation on a guidance](#) document for reporting on real-world evidence.